Kurs
+1,32%
Kurs
+1,32%
Open
39,00
High
40,20
Low
38,10
Close
38,30
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,11 MNOK
Likviditet
0,11 MNOK
Rel. mcap
0,02%
Antal aktier
2 769
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-05-06 | N/A | Årsstämma |
2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-04-30 | - | Kvartalsrapport 2024-Q1 |
2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2024-04-29 | - | Årsstämma |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2023-05-04 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2022-05-18 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-08-25 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2021-05-04 | - | Årsstämma |
2021-04-16 | - | Kvartalsrapport 2021-Q1 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-10-29 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2020-05-14 | - | Årsstämma |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-21 | - | Extra Bolagsstämma 2019 |
2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-07-13 | - | Extra Bolagsstämma 2018 |
2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-06-06 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-03-21 09:15:00
Moss, 21 March 2024
Due to private reasons the CEO of Gentian Diagnostics ASA, Hilja Ibert, has
decided to resign from her position. Hilja has played a key role in the growth
and success of Gentian Diagnostics ASA since 2018, and her dedication and
contributions to the company over the past years has been outstanding.
However, following the resignation of Hilja Ibert the Nomination Committee is
pleased to recommend her as a candidate for the position of new Chairperson of
the Board. Her wealth of experience and strategic insights will continue to
provide great value for Gentian Diagnostics ASA in this new capacity.
Simultaneously, Tomas Settevik, the Chairperson of the Board, has chosen not to
stand for re-election. Tomas has been instrumental in guiding the board and the
company. We express our thanks for his leadership of the past years.
The Company has initiated a search for Hilja IbertŽs replacement as CEO, in the
meantime Gentian Diagnostics' CFO, Njaal Kind, will serve as the acting CEO.
All the announced changes will take effect as of April 29, 2024, subject to the
approval by the General Meeting.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.